Answers are grounded in this paper and cite their sources.
Crystal and solution structures of the [PdII(η3‐allyl)] and of the [PdII(η3‐1,3‐diphenylallyl)] complexes, 4 and 5, respectively, with (4S)‐4‐benzyl‐2‐[2′‐(diphenylphosphino)phenyl]‐4,5‐dihydrooxazole (3) were determined by X‐ray crystallography and 2D‐NMR spectroscopy. Complex 4 proved to be disordered with both diastereoisomeric complexes in the crystal. The results of X‐ray and NMR experiments demonstrate a good agreement between solution and solid‐state equilibria of the two isomers. A comparison with dichloro{(4S)‐2‐[2′‐(diphenylphosphino)phenyl]‐4,5‐dihydro‐4‐phenyloxazole‐P,N}zinc(II) (2b) shows a surprising conformational stability of the coordinated phosphinooxazole ligand 3.
No takes yet. Share an insight, caveat, or question.
Baltzer et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: